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Background and purpose: The cardiovascular benefits of red wine consumption are often attributed to the antioxidant effects
of its polyphenolic constituents, including quercetin, catechin and resveratrol. Inhibition of cardiac voltage-gated sodium
channels (VGSCs) is antiarrhythmic and cardioprotective. As polyphenols may also modulate ion channels, and possess
structural similarities to several antiarrhythmic VGSC inhibitors, we hypothesised that VGSC inhibition may contribute to
cardioprotection by these polyphenols.
Experimental approach: The whole-cell voltage-clamp technique was used to record peak and late VGSC currents (INa) from
recombinant human heart NaV1.5 channels expressed in tsA201 cells. Right ventricular myocytes from rat heart were isolated
and single myocytes were field-stimulated. Either calcium transients or contractility were measured using the calcium-sensitive
dye Calcium-Green 1AM or video edge detection, respectively.
Key results: The red grape polyphenols quercetin, catechin and resveratrol blocked peak INa with IC50s of 19.4 mM, 76.8 mM
and 77.3 mM, respectively. In contrast to lidocaine, resveratrol did not exhibit any frequency-dependence of peak INa block.
Late INa induced by the VGSC long QT mutant R1623Q was reduced by resveratrol and quercetin. Resveratrol and quercetin
also blocked late INa induced by the toxin, ATX II, with IC50s of 26.1 mM and 24.9 mM, respectively. In field-stimulated
myocytes, ATXII-induced increases in diastolic calcium were prevented and reversed by resveratrol. ATXII-induced contractile
dysfunction was delayed and reduced by resveratrol.
Conclusions and implications: Our results indicate that several red grape polyphenols inhibit cardiac VGSCs and that this
effect may contribute to the documented cardioprotective efficacy of red grape products.
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long QT syndrome 3; NaV1.5, human heart voltage-gated sodium channel clone; NCX1.1, rat sodium–calcium
exchanger clone; VGSC, voltage-gated sodium channel.
Introduction
The rapid generation of net inward sodium current (peak INa)
via voltage-gated sodium channel (VGSC) activation is
responsible for the fast initiation of the cardiac action
potential. VGSCs normally inactivate within 10 ms and thus
sodium entry is usually limited to the depolarization phase
of the action potential. However, under several circum-
stances, the inactivation process is dysfunctional, resulting
in the development of a persistent current (late INa). This is
a key feature of several pathologies, including long QT
syndrome 3 (LQT3), in which congenital mutations in the
SCN5A gene lead to impaired inactivation of cardiac VGSCs,
resulting in a proarrhythmic prolonged action potential
(Wang et al., 1995; Janse, 1999). The increased influx of
sodium during the action potential plateau phase may
promote the formation of after-depolarizations, leading to
severe types of ventricular tachycardia such as torsade de
pointes (Janse, 1999). Furthermore, late INa has been
implicated in heart failure and during ischaemia-reperfusion
(I/R) injury (Maltsev et al., 1998; Xiao and Allen, 1999). The
accumulation of cytosolic sodium through persistent VGSC
activity may also lead to calcium overload via increased
reverse-mode sodium–calcium exchanger current (INa/Ca)
(Ravens and Himmel, 1999). This may cause the formation
of premature after-depolarizations and triggered activity,
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leading to ventricular arrhythmias as well as irreversible cell
injury via calcium loading and subsequent hypercontracture
(Janse, 1999).
VGSC inhibitors represent an important class of anti-
arrhythmic agents that include lidocaine and mexiletine
(Liu et al., 2003). Although some of these compounds possess
desirable features, such as frequency-dependence of block,
they may inhibit peak INa to the same extent as late INa.
Identification of novel VGSC inhibitors that selectively
inhibit late INa may provide useful, pathology-specific,
pharmacological tools. For example, the antianginal com-
pound ranolazine is proposed to act via inhibition of late
INa and provide cardioprotection by a subsequent reduction
of calcium overload without altering normal conduction
(Antzelevitch et al., 2004).
Many bioactive compounds contain one or more phenol
rings in their structure and several of them have demon-
strated cardioprotective efficacy. In particular, red grape
products such as red wine are important sources of several
dietary polyphenols with concentrations estimated to
range from 0.5 to 200mg ml1 for catechin and epicatechin,
0.25–50 mg ml1 for quercetin and 0.05–8.5 mg ml1 for
resveratrol (Bertelli et al., 1998; Ray et al., 1999; Leonard
et al., 2003; Gambuti et al., 2004; Manach et al., 2004). These
polyphenolic constituents are thought to be responsible
for the well-documented cardiovascular benefits of red wine
and for the ‘French Paradox’ of low mortality from
cardiovascular disease (Renaud and de Lorgeril, 1992).
Resveratrol is a well-characterized grape polyphenol that
has exhibited a multitude of cardioprotective properties
in vitro and in vivo (Frankel et al., 1993; Bertelli et al., 1995;
Pace-Asciak et al., 1995; Rotondo et al., 1998; Ray et al., 1999;
Hung et al., 2000; Cao and Li, 2004), including antiplatelet
(Bertelli et al., 1995; Pace-Asciak et al., 1995), antioxidative
(Frankel et al., 1993; Cao and Li, 2004), anti-ischaemic (Ray
et al., 1999; Hung et al., 2000) and antiarrhythmic (Hung
et al., 2000) effects. In models of I/R injury, resveratrol
improves functional recovery (Ray et al., 1999) and reduces
both infarct size (Ray et al., 1999; Hung et al., 2000) and the
severity of resultant ventricular arrhythmias (Hung et al.,
2000). The reductions in I/R-induced cell damage may result
from increased nitric oxide synthesis and other antioxidant
effects of resveratrol but a separate, as yet uncharacterized
mechanism may be involved, related to a reduction of
I/R-induced arrhythmias (Hung et al., 2004), suggestive of
an effect on cardiac ion channel function. For example,
resveratrol has recently shown inhibition of L-type calcium
channels and reductions in action potential duration (Liew
et al, 2005).
The red grape polyphenols catechin, quercetin and
resveratrol share the common structural feature of one or
more phenolic rings with VGSC-blocking drugs such as
lidocaine (Figure 1c). As the phenol group found in lidocaine
is thought to impart late VGSC block (Zamponi and French,
1993; Haeseler et al., 2002), we hypothesized that red grape
polyphenolic compounds may also inhibit peak and/or late
INa, contributing to the documented beneficial effects of
these grape polyphenols. Supporting this hypothesis, it has
recently been shown that resveratrol inhibits neuronal
VGSCs (Kim et al., 2005).
Methods
Animal care
Adult male Sprague–Dawley rats (200–250 g) were used for
experiments in accordance with guidelines set out by the
University of Alberta Animal Policy and Welfare Committee
and by the Canadian Council on Animal Care.
Cell culture and transfection
Human embryonic kidney tsA201 cells, a simian virus
(SV-40)-transformed derivative of HEK-293 cells, were main-
tained in Dulbecco’s modified Eagle’s medium supplemented
with 2 mM L-glutamine, 10% foetal calf serum and 0.1%
penicillin/streptomycin at 371C in 5% CO2. Passage numbers
ranging from 20 to 60 were used. Cells were plated at
50–70% confluence onto 35 mm culture dishes 3–4 h before
transfection. Mammalian expression vectors encoding the
human heart VGSC clone (NaV1.5) – either wild-type or with
the R1623Q mutation (see below) – and green fluorescent
protein (pGL, Life Technologies, Burlington, Canada), as a
visual marker, were co-transfected into cells using the
calcium phosphate precipitation technique. NaV1.5 was
generously provided by Dr AM Brown (Case Western Reserve
University, Cleveland, OH, USA). Cells were plated at 10–
30% confluence onto cover slips 40–45 h after transfection.
Single cells were used for electrophysiological recording
during the subsequent 30-h period. For experiments using
the rat sodium–calcium exchanger (NCX1.1), tsA201 cells
were infected with 30 PFU cell1 of an NCX1.1 construct in
an adenovirus construct, generously provided by Dr J Lytton
(University of Calgary, Calgary, Alberta, Canada) and Dr JY
Cheung (Geisinger Medical Center, Danville, PA, USA).
NaV1.5 Mutagenesis
Amino acid substitution of an arginine residue with a
glutamine at position 1623 (R1623Q) of the NaV1.5
a-subunit was performed using polymerase chain reaction
(PCR). A 569 bp cDNA of NaV1.5 was amplified using the
oligonucleotide primers ‘1623SeqF’ (50-AGAGCAGCCTCAG
TGGGA-30) (base pair 4306 at start) and ‘1623L’ (50-GGCGG
ATGACTTGGAAGA-30) (Operon Biotechnologies Inc., German-
town, MD, USA). A 468 bp cDNA of NaV1.5 was ampli-
fied concurrently using the primers ‘1623U’ (50-GACGCTCT
TCCAAGTCAT-30) and ‘1623SeqR’ (base pair 5330 at end)
(50-ACGCTGAAGTTCTCCAGGA-30). The two PCR products
were purified via gel-extraction and combined in a second
round of PCR with the primer pair ‘1623SeqF’ and
‘1623SeqR’. The resulting 1024 bp PCR product was digested
with BsrGI to yield a 960 bp insert, which was then sub-
cloned back into wild-type NaV1.5 to produce the R1623Q
construct as confirmed by sequencing.
Electrophysiology
Pipettes were pulled from borosilicate glass capillary tubing
(Warner instruments, Hamden, CT, USA) using a P-87
micropipette puller (Sutter Instruments, Novato, CA, USA)
and the tips were fire-polished, yielding resistances of
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1–4 MO. The pipette solution contained (in mM): 130 CsCl, 5
NaCl, 5 tetraethylammonium (TEA)-Cl, 2.5 2-[4-(2-hydro-
xyethyl)-1-piperazinyl]ethanesulphonic acid (HEPES), and
1 ethylene glycol-bis-(2-aminoethyl ether)-N,N,N0,N0-tetra-
acetic acid (EGTA). The pH was adjusted to 7.2 with CsOH.
2 mM MgATP was added immediately before use. Cells
were bathed in extracellular solution containing (in mM):
140 NaCl, 10 HEPES, 1 CaCl2, 1.4 MgCl2, 5 KCl and 10
glucose (pH adjusted to 7.4 with NaOH). Solutions were
applied to cells using a multi-input perfusion pipette (switch
time o2 s). Whole-cell voltage-clamp was used to record
macroscopic INa. Data were recorded using an Axopatch
200B patch-clamp amplifier and Clampex 8 software (Axon
Instruments, Foster City, CA, USA). Test pulses to 20 mV
from a resting potential of 100 mV lasted 80 ms with a cycle
length of 0.2 Hz or 20 ms at 10 Hz. When appropriate, late INa
was measured 50 ms after initiation of the test pulse. Parallel
current–voltage curves were also recorded and data fitted
to the Boltzmann equation to yield Gmax curves. Owing to
space-clamp concerns, data were discarded if the resulting
slope factor was o6 mV. INa/Ca measurements were obtained
using the inside-out excised-patch patch-clamp technique.
Outward reverse-mode currents were elicited by rapidly
(o2 s) switching the solution flowing from a multi-input
perfusion pipette from a cesium-based intracellular solution
containing (in mM): 120 CsCl, 20 TEA, 5 HEPES, 10 glucose,
2 MgATP, 1.4 MgCl2, 4.28 CaCl2, and 5 EGTA to a sodium-
based intracellular solution containing (in mM): 30 CsCl, 90
NaCl, 20 TEA, 5 HEPES, 10 glucose, 2 MgATP, 1.4 MgCl2, 4.28
CaCl2, and 5 EGTA. The pH of these solutions was adjusted
to 7.2 with CsOH.
Myocyte isolation
Rats were killed with pentobarbital (150 mg kg1, i.p.)
according to University of Alberta Animal Policy and Welfare
Committee and Canadian Council on Animal Care Guide-
lines. The hearts were then removed, and myocytes were
obtained from the right ventricle by enzymic dissociation
using standard protocols previously described (Shimoni
et al., 1998). After 1 h, cells were placed on coverslips for
observation at 200 and were superfused with control
solution containing (in mM): 140 NaCl, 10 HEPES, 2.0 CaCl2,
1.4 MgCl2, 5 KCl and 10 glucose.
Measurement of calcium transients
Right ventricular myocytes were loaded with 4 mM of the
calcium-sensitive fluorescent probe Calcium Green-1AM
(Molecular Probes, Eugene, OR, USA) for 30 min at room
temperature followed by 30 min at 371C. After loading, cells
were washed and placed on coverslips for observation at
200 with a CK40 inverted microscope (Olympus, Melville,
NY, USA). Cells were then superfused with control solution
as described above and field-stimulated at 1 Hz. A Photon
Technology International Photomultiplier Detection System
(PTI, Lawrenceville, NJ, USA) with Clampex 8 software was
used for data acquisition. Calcium Green-1AM was excited
with 480 nm light, and the emitted light intensity at 520 nm
was digitized. Diastolic calcium was measured as a percen-
tage of control and normalized to the peak amplitude of the
calcium transient (Baczko et al., 2005).
Measurement of cell shortening
Cell shortening was measured using a video edge detector
(Crescent Electronics, Salt Lake City, UT, USA). Myocytes
were field-stimulated at 1 Hz with 2 ms square pulses at a
constant current 20% above threshold value. Cell shortening
was expressed as fractional change in cell length (DL¼ (L0L)
L0
1, where L is length upon stimulation and L0 is resting cell
length). Irregularly shaped contractions were defined as
dysfunctional and the number of dysfunctional contractions
was then assessed as a percentage of total contractile events.
All experiments were performed at room temperature
(21711C).
Statistics
Data were analysed using Clampex 8, Microsoft Excel and
Origin Graph. Data are presented as means7s.e.m. or as a fit
to the Boltzmann equation. Statistical analyses of data were
performed using the Student’s paired or unpaired t-test or
ANOVA as appropriate. Po0.05 was considered statistically
significant.
Drugs and chemicals
Grape extract (BioVin, Cyvex Nutrition Inc., CA, USA) was
prepared as a 15 mg ml1 stock solution in dimethyl sulph-
oxide. All other drugs used in this study were obtained from
Sigma (St Louis, MO, USA) and were also prepared as 1000
stock solutions in dimethyl sulphoxide: Resveratrol at 10, 20,
50, 100 and 200 mM; quercetin at 1, 2, 5, 10, 20 and 50 mM;
lidocaine at 50 mM; N-acetylcysteine at 200 mM and the
VGSC inactivation inhibitor Anemonia sulcata toxin (ATX) II,
used to induce a late INa (Chahine et al., 1996), at 3 or 5mM.
Each stock solution was diluted 1000-fold in extracellular
bath solution directly before use, to yield micromolar or
nanomolar concentrations. Dimethyl sulphoxide (0.1%
v v1) was used in control solutions.
Results
VGSC block
In order to first assess the VGSC blocking properties of grape-
derived polyphenols, we tested the effects of grape extract
on peak INa in a recombinant system using tsA201 cells.
Application of 15 mg ml1 grape extract showed significant
inhibition of peak INa (Figure 1a and b). As red grape extract
and red wine contain a variety of bioactive poly-
phenolic compounds, we tested the effects of three of the
most commonly occurring polyphenols, catechin, quercetin
and resveratrol (Figure 1c), individually on recombinant INa
(Figure 2a–c). Concentration-dependence studies (Figure 2e)
yielded IC50s for the effects of resveratrol and quercetin on
INa of 77.378.20 mM and 19.472.05 mM. Catechin inhibited
peak INa with an IC50 of 76.875.15 mM. Voltage-dependence
of activation (Gmax50) in the presence of 50 mM resveratrol
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(48.770.942 mV) or 10 mM quercetin (43.370.498mV)
was not significantly different from control (48.17
1.40 mV) (Figure 2f); nor was steady-state availability, for
which Gmax50 was 93.270.596 mV for control, 96.67
0.936 mV for quercetin and 96.771.21 mV for resveratrol
(Figure 2g). To ascertain whether the VGSC blocking effects
of these polyphenols could be attributed to the documented
antioxidant properties of these compounds, we tested the
effects of the structurally unrelated antioxidant N-acetyl-
cysteine (Figure 1c, 200mM) and found that it had no signi-
ficant effect on INa (Figure 2d and e).
Frequency-dependence
One of the key properties of the antiarrhythmic agent
lidocaine (Figure 1c) is the use- or frequency-dependence of
its VGSC block. Therefore, we compared the frequency-
dependence of resveratrol’s INa block to that of lidocaine.
At the higher stimulation frequency of 10 Hz, resveratrol
(50 mM) and lidocaine (50 mM) inhibited peak INa by 3877
and 6774%, respectively (Figures 3a–c). In contrast, at a
lower pulse frequency of 0.2 Hz, resveratrol (50 mM) and
lidocaine (50 mM) inhibited peak INa equally (Figure 3a–c).
Upon washout, the effect of lidocaine was fully reversible
while that of resveratrol was only partly reversible
(Figure 3d).
Late INa inhibition
Induction of late noninactivating INa has been associated
with many of the pathological characteristics of I/R injury
(Undrovinas et al., 1992; Wu and Corr, 1994; Ju et al., 1996;
Ward and Giles, 1997) and has been suggested to contribute
to observed ionic disturbances and consequent electrical and
contractile dysfunction (Van Emous et al., 1997; Karmazyn
et al., 1999). In addition, the expression of mutated VGSCs
in congenital LQT3 may cause proarrhythmic increases in
action potential duration (APD) by increasing noninactivat-
ing late INa leading to an increase in the QT interval and
the precipitation of torsade de pointes (Wang et al., 1997;
Janse, 1999). As inhibition of late VGSC activity has the
potential to be cardioprotective and antiarrhythmic, we
tested the effects of resveratrol and quercetin on mutant
NaV1.5 channels containing the LQT3 mutation R1623Q
(Figure 4a). Resveratrol (50 mM) reduced both peak and late
INa but exhibited a higher efficacy for late INa block in the
R1623Q LQT3 NaV1.5 mutant (Figures 4b and d). In contrast,
quercetin (10 mM) showed no selectivity between peak and
late R1623Q INa (Figures 4c and d).
Figure 1 (a) Representative traces of recombinant INa through
VGSCs expressed in tsA201 cells in the presence of 0 or 15 mg ml1
grape extract. (b) Grape extract (15 mg ml1, n¼4, Po0.05)
inhibited peak recombinant INa but did not wash out. (c) Structural
formulae of resveratrol, catechin and quercetin, antioxidant poly-
phenols with substituted aromatic rings. Lidocaine is a VGSC blocker
containing a similar aromatic group. N-acetylcysteine is an anti-
oxidant without structural similarity to these compounds.
Figure 2 (a) Representative recombinant INa traces in the presence
of 0, 10, 20, 50 or 100mM resveratrol. (b) Representative recombi-
nant INa traces in the presence of 0, 1, 10, 20 or 50mM quercetin.
(c) Representative recombinant INa traces in the presence of 0, 10,
20, 50, or 200mM catechin. (d) Representative traces of recombinant
INa in the presence of 0 or 200mM N-acetylcysteine. (e) Concentra-
tion–response curves for the block of peak recombinant INa by
catechin, quercetin, resveratrol and N-acetylcysteine (n¼4–11).
(f) Voltage-dependence of activation at varying test potentials is
unchanged with 50mM resveratrol or 10mM quercetin present (n¼
9–13). (g) Inactivation at varying prepulse potentials is unchanged
with 50mM resveratrol or 10mM quercetin present (n¼5).
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In order to further test the effects of resveratrol and
quercetin on late INa, we used the toxin, Anemonia sulcata
toxin II (ATXII) (5 nM), to selectively induce a noninactivat-
ing late INa in tsA201 cells expressing wild-type NaV1.5
(Figure 5a and c). At 50 ms, ATXII induced a 20-fold increase
in late INa that was inhibited by resveratrol with an IC50 of
2673.0mM. (Figure 5b), a threefold more potent block than
that of peak INa (IC50 of 7778.2mM) (Figure 5b). In contrast
to the results found using the R1623Q mutant, quercetin
showed a significant difference between its effect on late INa
(2573.2 mM) and peak INa (1472.1 mM, Po0.05) (Figure 5d)
when late INa was induced with ATXII.
Myocyte contractility and calcium handling
The studies of resveratrol on recombinant NaV1.5 channels
suggest that some of its cardioprotective effects documented
in native systems may involve inhibition of INa, particularly
late INa. In order to test the ability of resveratrol to reduce
myocardial dysfunction, we used ATXII in isolated rat right
ventricular myocytes to specifically induce late INa (Chahine
et al., 1996) and hence alterations in calcium homeostasis
expected from reverse-mode INa/Ca as well as subsequent
contractile dysfunction (Ravens and Himmel, 1999).
After 5 min of application, 5 nM ATXII increased diastolic
calcium (Figure 6a), but when resveratrol (50mM) was present
at the beginning of the experiment, the ATXII-induced
elevation in diastolic calcium was prevented. Subsequent
removal of resveratrol allowed ATXII to elevate diastolic
calcium again (Figure 6b and d). Resveratrol was also found
to reverse the effects of ATXII on diastolic calcium: after
Figure 3 (a) Representative time course of peak recombinant INa
before, during and after application of 50mM resveratrol at a pulse
frequency of 10 Hz or 0.2 Hz. (Inset) Representative recombinant INa
traces in the presence of 0 or 50mM resveratrol at a pulse frequency
of 10 Hz. (b) Representative time course of peak recombinant INa
before, during and after application of 50mM lidocaine at a pulse
frequency of 10 Hz or 0.2 Hz. (Inset) Representative recombinant INa
traces in the presence of 0 or 50mM lidocaine at a pulse frequency of
10 Hz. (c) At a pulse frequency of 0.2 Hz, resveratrol and lidocaine, at
50mM each, inhibit peak INa to a similar extent (n¼6–7). At a pulse
frequency of 10 Hz, lidocaine (50 mM, n¼7) inhibits peak INa to a
greater extent than does resveratrol (50 mM, n¼7). (d) Peak INa
blocked by 50mM lidocaine returns to control levels upon washout;
peak INa block by 50mM resveratrol shows no significant washout
(n¼6). #Po0.05 within groups; *Po0.05 between groups.
Figure 4 (a) Normalized traces comparing INa from mutant and
wild-type VGSCs expressed in tsA201 cells. (b) Representative traces
of INa through mutant (R1623Q) VGSCs in the presence of 0 or
50mM resveratrol. (c) Representative traces of INa through R1623Q
VGSCs in the presence of 0 or 10mM quercetin. (d) Peak and late INa
through R1623Q VGSCs in the presence of 50mM resveratrol or
10mM quercetin. All groups were normalized to their controls. Late
R1623Q INa was blocked to a greater extent than peak INa during
application of 50mM resveratrol (n¼7) and late R1623Q INa was
blocked to the same extent as peak INa during application of 10mM
quercetin (n¼10). *Po0.001.
Figure 5 (a) Representative recombinant INa traces in the presence
of 5 nM ATXII and 0, 10, 20, 50 or 100mM resveratrol. (Left inset).
Representative recombinant INa traces in the presence of 0 or 5 nM
ATXII. (Right inset) Expanded trace of late INa in the presence of 5 nM
ATXII and 0, 10, 20, 50 or 100mM resveratrol (40–60 ms after the
depolarizing pulse). (b) Concentration–response curves for the block
of peak INa and ATXII-induced late INa by resveratrol (n¼5–11).
(c) Representative recombinant INa traces in the presence of 5 nM
ATXII and 0, 10, 20, 50 or 100mM quercetin. (Inset) Expanded
trace of late INa in the presence of 5 nM ATXII and 0, 10, 20, 50
or 100 mM quercetin (40–60 ms after the depolarizing pulse).
(d) Concentration–response curves for the block of peak INa and
ATXII-induced late INa by quercetin (n¼4).
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5 min treatment with ATXII, addition of resveratrol reduced
diastolic calcium to control values (Figure 6c and e). The
application of resveratrol alone to cardiomyocytes had no
effect on the amplitude (9176% of control) nor on the
systolic (9672% of control) or diastolic (9474% of control)
levels of the calcium transient (results not shown, n¼3).
While large sustained elevations in intracellular calcium
eventually lead to myocyte hypercontracture, this is usually
preceded by alterations in contractile function. After-depo-
larizations generated by sustained sodium levels or excessive
calcium levels may be manifested as premature contractions.
Accordingly, we measured the effects of ATXII and resvera-
trol on the contractile behaviour of field-stimulated myo-
cytes. ATXII (3 nM)-induced dysfunction in cardiomyocyte
contractility about 140 s after addition (Figures 7a and c).
Application of 100 mM resveratrol during the first 5 min
of ATXII treatment delayed the initiation of contractile
dysfunction threefold (Figures 7b and c). Analysis of the
frequency of abnormal contractions that exhibited prema-
ture peaks indicative of after-depolarizations revealed that in
the presence of ATXII, resveratrol abolished the occurrence
of these abnormal contractions (Figure 7d).
Role of sodium/calcium exchanger
Increases in late INa lead to elevated intracellular sodium that
is thought to favour reverse-mode sodium/calcium exchange
(NCX) and the subsequent influx of calcium into myocytes
(Ravens and Himmel, 1999). Therefore, a plausible alter-
native explanation for the effects of resveratrol may involve
a direct inhibition of reverse-mode NCX. In order to test this
experimentally, we expressed recombinant rat NCX1.1 in
tsa201 cells and measured INa/Ca in the absence and presence
of resveratrol (Figure 8a). Resveratrol, at the concentration
(50 mM) shown to reduce calcium loading in myocytes, had
no significant effect on reverse-mode NCX (Figure 8b).
Discussion
Grape products contain flavonoids and stilbenes, including
catechins, quercetin and resveratrol, which have demon-
Figure 6 (a–c) Representative recordings of calcium green-1AM
fluorescence during a 2 min control period followed by a 10 min
treatment period. Expanded traces show calcium transients at the 2,
7 and 12 min time points. (a) Calcium transient recording in which
the 2 min control period is followed by 10 min of 5 nM ATXII alone.
(b) Calcium transient recording in which the 2 min control period is
followed by 5 min of treatment with 5 nM ATXII plus 50mM
resveratrol and 5 min of treatment with 5 nM ATXII. (c) Calcium
transient recording in which the 2 min control period is followed by
5 min of treatment with 5 nM ATXII and 5 min of treatment with 5 nM
ATXII plus 50mM resveratrol. (d) After the first 5 min of treatment,
5 nM ATXII alone increased diastolic calcium, whereas the addition of
50mM resveratrol during the first 5 min of treatment prevented an
increase; **Po0.001. (e) At the end of treatment, 5 nM ATXII alone
increased diastolic calcium; addition of 50mM resveratrol during the
final 5 min of treatment reversed ATXII-induced changes; *Po0.05
(n¼6 in all groups).
Figure 7 (a, b) Representative recordings of cardiomyocyte short-
ening. Expanded traces show contractility at the 2 and 4 min time
points. (a) 3 nM ATXII produces contractile dysfunction. (b) Contrac-
tile dysfunction occurs later and to a lesser extent in the presence
of both 3 nM ATXII and 100mM resveratrol. (c) 3 nM ATXII produces
contractile dysfunction; with application of 100mM resveratrol
during the first 5 min of ATXII treatment, contractile dysfunction is
significantly delayed; *Po0.001. (d) 3 nM ATXII produces contractile
dysfunction as measured by the occurrence of abnormal contrac-
tions; with the addition of 100mM resveratrol, a significantly smaller
incidence of abnormal contractions is observed; *Po0.001 (n¼7 in
all groups).
Figure 8 (a) Representative traces of recombinant NCX1.1 current
(INa/Ca) in the presence or absence of 50mM resveratrol. (b) The ratio
of late to peak INa/Ca in the presence of 50mM resveratrol (n¼3) is
not significantly different from control (n¼3). P40.05.
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strated benefits in vitro and in vivo. Consumption of red wine
(20–30 g alcohol day1) has been associated with a 40%
reduction in risk of coronary heart disease (CHD) and a diet
rich in flavonoids (30 mg day1) has been linked to a 50%
decrease in CHD mortality (Renaud and de Lorgeril, 1992).
While polyphenols have cardioprotective effects related to
their antioxidant properties (Frankel et al., 1993; Hung et al.,
2000; Brito et al., 2002), it has emerged in recent years that
they may also interact with intracellular and cell-surface
proteins, including ion channels, independently of these
actions (Li et al., 2000; Dobrydneva et al., 2002; Wallerath
et al., 2002; Cao and Li, 2004; Orsini et al., 2004; Kim et al.,
2005). Examples of these include potassium channels (Orsini
et al., 2004), calcium channels (Dobrydneva et al., 2002) and
neuronal sodium channels (Kim et al., 2005).
In addition, we now show that several grape polyphenols
directly inhibit cardiac VGSCs and that this mechanism may
contribute to the cardioprotective effects of these poly-
phenols. Specifically, our data demonstrate that application
of red grape extract at a concentration relevant to the diet
(15 mg ml1; Manach et al., 2004), significantly inhibits wild-
type VGSCs (Figure 1a and b). Three of the most common
polyphenols in grape extract are quercetin, catechin and
resveratrol (Figure 1c), and these polyphenols, in that order
of potency, dose-dependently inhibit INa (Figure 2e).
We also provide direct evidence that the polyphenol
resveratrol may exert some of its effects via inhibition
of late INa. Two models of late INa were used, differing in
their mechanisms: the LQT3 mutant R1623Q introduces
an intrinsic change in the structure of the VGSC, uncoupling
activation and inactivation (Kambouris et al., 1998), and the
toxin ATXII, by destabilizing the inactivated state (Chahine
et al., 1996), allows the VGSC to more readily return to the
open state. The latter model may be used to pharmacologi-
cally manipulate late INa in the recombinant system and use
these results as the basis for experiments on native myocytes.
Resveratrol inhibits late INa to a B2-fold greater extent than
peak INa in both models of late INa (Figures 4d and 5b). In
comparison, quercetin also displayed some selectivity in
inhibiting late INa vs peak INa block, although not as great as
resveratrol and only in the ATXII model of late INa (Figure 4d
vs Figure 5b and d). These differences may be attributable to
the structural differences between resveratrol and quercetin
discussed below.
The ability of resveratrol to preferentially inhibit late INa
in the heart has direct relevance to pathophysiological
states such as LQT3, I/R injury and arrhythmias. In LQT3,
prolongation of the APD can be attenuated by reduced late
INa, leading to a lower likelihood of after-depolarization
formation and subsequent torsade de pointes arrhythmias.
The antianginal agent ranolazine exhibits selective inhibi-
tion of this current, protecting the heart by preventing APD
prolongation (Antzelevitch et al., 2004). In the case of I/R
injury, increases in intracellular sodium via late INa and
sodium–hydrogen exchanger activity (Lazdunski et al., 1985;
Van Emous et al., 1997; Karmazyn et al., 1999) are thought to
facilitate calcium overload via reverse-mode INa/Ca, thus a
reduction in sodium load via late INa block by polyphenols
may reduce or prevent increases in intracellular calcium,
reducing cellular damage in the form of irreversible cellular
hypercontracture and the generation of arrhythmias. In
either of these situations, frequency-independent inhibition
of peak INa may be ineffective or even detrimental. Our
results show that while resveratrol both prevents and
reverses increases in diastolic calcium induced by ATXII,
a VGSC-specific toxin (Figure 6), produces a three-fold delay
in ATXII-induced contractile dysfunction (Figure 7c) and
reduces the incidence of abnormal contractions, defined as
premature peaks (Figure 7d), it has no effects in the absence
of pathophysiological conditions (results not shown) and
does not produce a cessation of synchronously stimulated
calcium transients or myocyte contractility, indicating that
it is acting primarily through late and not peak VGSC
inhibition. The observed lack of direct effect of resveratrol on
reverse-mode INa/Ca (Figure 8) further suggests that the
beneficial effects of resveratrol on dysfunctional calcium
handling and contractility induced by ATXII involve a
specific inhibition of persistent VGSC, leading indirectly to
reduced reverse-mode INa/Ca. This does not exclude an
additional role for L-type calcium channel inhibition (Liew
et al., 2005), which could explain discrepancies between the
effect of resveratrol on INa and on calcium handling and
contractility. It is plausible that other ion channels may also
be modulated by these polyphenols, which should be further
characterized in future studies.
VGSC blockers, like polyphenols, have a substituted
aromatic ring as a common structural feature (Figure 1c). It
is thought to be the moiety responsible for binding to their
target site, a cluster of hydrophobic residues at the interface
of four segments lining the VGSC pore (Ragsdale et al., 1994;
Haeseler et al., 2001; Yarov-Yarovoy et al., 2002). In studies in
which lidocaine is chemically ‘dissected’ into its hydrophilic
and hydrophobic components (Zamponi and French, 1993;
Haeseler and Leuwer, 2002; Haeseler et al., 2002), the polar,
amine portion exhibits fast, use-dependent open-state block
involving changes in channel conductance (Zamponi and
French, 1993), while the phenolic part exhibits less
frequency-dependence in its inhibition of INa, in which
there are changes in open probability and rapid recovery
from inactivated-state block (Zamponi and French, 1993;
Haeseler et al., 2002). Our finding that resveratrol does not
incur use-dependent block of VGSCs further confirms the
importance of the charged amine moiety in use-dependent
block by lidocaine. It has been theorized that lack of use-
dependence of resveratrol could be related to its rapid
dissociation from the VGSC (Kim et al., 2005); however,
our observations of an absence of washout indicate this to be
unlikely. Furthermore, our data indicate that, as with simple
phenolics, voltage-dependence of activation and steady-state
availability are not affected by resveratrol or quercetin
(Figure 2f and g).
A key finding from this study is the B2-fold selectivity of
resveratrol for late over peak INa compared to the absence
of selectivity in the case of quercetin. An analysis of their
structures (Figure 1c) suggests that quercetin’s bulkier
structure, richer in electron-donating groups, may sterically
hinder interaction with residues deeper in the VGSC’s pore
responsible for allowing necessary conformational changes
for a late current to result (Yarov-Yarovoy et al., 2002; Leuwer
et al., 2004). Differences in the sodium channel residues
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involved in coupling of activation to inactivation and in
inactivation state stabilization may be responsible for
discrepancies between results for resveratrol and quercetin
in the two models of late INa. In addition, our observation
that quercetin is a much more effective VGSC inhibitor than
catechin (IC50 values of 19.4 and 76.8 mM, respectively)
despite almost identical structures suggests that the presence
of the conjugated carbonyl on quercetin’s second ring
structure may contribute to the observed increase in VGSC
inhibitory efficacy.
Additional benefits of resveratrol and other red grape
polyphenols may be contributed by the well-documented
antioxidant properties of the polyphenols in reducing
reperfusion-induced free-radical damage (Hung et al., 2002;
Valdez et al., 2002). Changes in redox potential or surface
charge may also account for some ionic current block
(Bhatnagar et al., 1990), therefore it is possible that the
antioxidant properties of polyphenols may contribute to the
observed VGSC inhibition. However, parallel experiments
with N-acetylcysteine, a structurally unrelated antioxidant
lacking a substituted phenolic group (Figure 1c), demon-
strated no effect on INa (Figure 2d and e), making this
an unlikely mechanism in this case.
Polyphenol concentrations effective for free-radical
scavenging are in the 5–20 mM range in vitro (Alvarez et al.,
2002; Leonard et al., 2003) and in perfused rat hearts
showing ischaemic recovery (Ray et al., 1999), indicating
potentially clinically relevant doses. While concentrations of
individual polyphenols in the 50 mM range, as used in this
study, are unlikely to be reached in human plasma after
moderate red wine consumption (Vitaglione et al., 2005), a
polyphenol-rich diet may include several dietary sources,
raising the total polyphenol concentration above that for
each compound alone, possibly imparting additive effects
on inhibition of INa.
Our observations that red grape extract and resveratrol are
resistant to washout (Figures 1b and 3d) indicate that
membrane partitioning and subsequent binding to VGSCs
may contribute to the efficacy of these polyphenols even at
lower apparent plasma concentrations. This is supported by
evidence suggesting that dietary polyphenols may accumu-
late in tissues, resulting in a higher local concentration of
these compounds. For example, resveratrol concentrations
were 2.4-fold higher in mouse liver and heart than the
concentrations reached in plasma (Sale et al., 2004). More-
over, many polyphenols exist in both their aglycone
and their glycoside forms in plasma (Vitrac et al., 2003;
Manach et al., 2004); the latter are cleaved by endogenous
b-glucosidases to increase polyphenol bioavailability.
In summary, we have demonstrated that several common
red grape polyphenols are effective inhibitors of peak and/or
late INa. This mechanism may contribute to the observed
protective effects of red grape/wine ingestion on cardiac
function during I/R injury. This novel protective mechanism
involves improved myocyte calcium handling and contrac-
tility that is downstream of inhibition of late INa. Given
the important role that ion channels play in a variety
of disease states, further studies on the modulatory effects
of grape polyphenols on other types of ion channels are
warranted.
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